NRBO Stock Summary and Trading Ideas (Neurobo Pharmaceuticals | NASDAQ:NRBO)

NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

Neurobo Pharmaceuticals trades on the NASDAQ stock market under the symbol NRBO.

As of May 16, 2024, NRBO stock price climbed to $4.31 with 4,821 million shares trading.

NRBO has a beta of 0.54, meaning it tends to be less sensitive to market movements. NRBO has a correlation of 0.01 to the broad based SPY ETF.

NRBO has a market cap of $21.14 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, NRBO stock traded as high as $1,576.82 and as low as $2.89.

The top ETF exchange traded funds that NRBO belongs to (by Net Assets): VXF, VTI, DFAS, DFAT.

NRBO has underperformed the market in the last year with a return of -9.1%, while the SPY ETF gained +30.0%. In the last 3 month period, NRBO fell short of the market, returning -10.8%, while SPY returned +5.9%. However, in the most recent 2 weeks NRBO has outperformed the stock market by returning +17.1%, while SPY returned +6.0%.

NRBO support price is $3.97 and resistance is $4.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NRBO stock will trade within this expected range on the day.